References on Arthritis Research Using ALZET® Osmotic Pumps

16328 Dong, Y., Liu, H., Zhang, X., Xu, F., Qin, L., Cheng, P., Huang, H., Guo, F., Yang, Q., Chen, A. Inhibition of SDF-1alpha/CXCR4 Signalling in Subchondral Bone Attenuates Post-Traumatic Osteoarthritis. Int J Mol Sci 2016; 17(-6-):. >>> AMD3100; PBS; SC; Mice; 1004; Controls received mp w/ vehicle and sham operation; animal info (C57BL/6J mice (30 males, 2 months old)); immunology; (AMD3100 is an immunostimulant); inhibitor of CXCR4; transected the anterior cruciate ligament on the right knee; caused joint instability; Dose (180 ug/day);.

16092 Appleton, C. T., Usmani, S. E., Pest, M. A., Pitelka, V., Mort, J. S., Beier, F. Reduction in disease progression by inhibition of transforming growth factor alpha-CCL2 signaling in experimental posttraumatic osteoarthritis. Arthritis Rheumatol 2015; 67(-10-):2691-701. >>> AG1478; RS504393; DMSO; water, deionized; SC; rat; 2ML4; Controls received mp w/ vehicle; functionality of mp verified by plasma levels and knee articular cartilage; pumps replaced every 4 weeks; %50 of DMSO; long-term study; enzyme inhibitor (EGFR and CCR2 inhibitors); EGFR inhibitor AG1478, CCR2 inhibitor RS504393; Dose: (AG1478) 21 nmoles/kg/hour; (RS504393) 200 nmoles/kg/hour.

15834 Gisela Segond von Banchet,, Christian K€onig,, Jessica Patzer,, Annett Eitner,, Johannes Leuchtweis,, Matthias Ebbinghaus,, Michael K. Boettger,, Hans-Georg Schaible  ARTHRITIS&RHEUMATOLOGY 2016; 68(-2-):532-541. >>> Anakinra; SC; Rat; 2ML4; Controls received mp w/ saline; animal info (female, Lewis, 6-8 weeks old, 160-180g); animal info (female, Lewis, 6-8 weeks old, 160-180g); immunology; delayed delivery for 5 days; Dose (53 mg/kg/day);.

15112 Thomas, N.P., Li, P.C., Fleming, B.C., Chen, Q., Wei, X.C., Pan, X.H., Li, G., Wei, L., Wei, L. Attenuation of cartilage pathogenesis in post-traumatic osteoarthritis (PTOA) in mice by blocking the stromal derived factor 1 receptor (CXCR4) with the specific inhibitor, AMD3100. JOURNAL OF ORTHOPAEDIC RESEARCH 2015; 33(--):1071-1078. >>> AMD3100; SC; Mice; 1004; Controls received mp w/ PBS or empty pumps; animal info (male, C57BL6J, 2 months old); pumps replaced every 4 weeks; long-term study;.

15053 Nieto, F.R., Clark, A.K., Grist, J., Chapman, V., Malcangio, M., Malcangio, M. Calcitonin Gene-Related Peptide-Expressing Sensory Neurons and Spinal Microglial Reactivity Contribute to Pain States in Collagen-Induced Arthritis. ARTHRITIS&RHEUMATOLOGY 2015; 67(--):1668-1677. >>> Calcitonin gene-related peptide (8-37); CSF/CNS (intrathecal); Rat; 2001; Controls received mp w/ vehicle; animal info (female, Lewis, 180-200g); behavioral testing (Von Frey filaments; Plantar test); immunology; peptides;.

14949 Hamilton, C.B., Pest, M.A., Pitelka, V., Ratneswaran, A., Beier, F., Chesworth, B.M., Beier, F. Weight-bearing asymmetry and vertical activity differences in a rat model of post-traumatic knee osteoarthritis. OSTEOARTHRITIS AND CARTILAGE 2015; 23(--):1178-1185. >>> Water, distilled; SC; Rat; 2ML4; Controls received mp w/ vehicle; animal info (male, Sprague Dawley, 301-325g); pumps replaced every 4 weeks; post op. care (buprenorphine 50 ug/kg SC); behavioral testing (static weight bearing, exploratory motor behavior); long-term study;.

14796 Radwan, M., Wilkinson, D.J., Hui, W., Destrument, A.P.M., Charlton, S.H., Barter, M.J., Gibson, B., Coulombe, J., Gray, D.A., Rowan, A.D., Young, D.A., Young, D.A. Protection against murine osteoarthritis by inhibition of the 26S proteasome and lysine-48 linked ubiquitination. ANNALS OF THE RHEUMATIC DISEASES 2015; 74(--):1580-1587. >>> MG132; DMSO; PEG 300; SC; Mice; 1004; Controls received mp w/ vehicle; animal info (C57BOL6J or mutant-Ub transgenic, 8 weeks old); pumps replaced every 4 weeks; 50% DMSO used; 50% PEG 300; long-term study; enzyme inhibitor (proteasome, general);.

14323 Nishimura, K., Saegusa, J., Matsuki, F., Akashi, K., Kageyama, G., Morinobu, A., Nishimura, K. Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice. ARTHRITIS&RHEUMATOLOGY 2014; 66(--):S1271-S1272. >>> Tofacitinib; DMSO; SC; Mice; Controls received mp w/ vehicle; animal info (female, SKG mice, arthritis induction); immunology;.

14281 Litherland, G.J., Hui, W., Elias, M.S., Wilkinson, D.J., Watson, S., Huesa, C., Young, D.A., Rowan, A.D., Rowan, A.D. Glycogen Synthase Kinase 3 Inhibition Stimulates Human Cartilage Destruction and Exacerbates Murine Osteoarthritis. ARTHRITIS&RHEUMATOLOGY 2014; 66(--):2175-2187. >>> CT99021; DMSO; PEG 400; SC; Mice; Controls received mp w/ vehicle; animal info (male, C57BL6J, 10 weeks old); 50% PEG 400 used; 50% DMSO used; CT99021 is a GSK-3 inhibitor;.

14207 Furman, B.D., Mangiapani, D.S., Zeitler, E., Bailey, K.N., Horne, P.H., Huebner, J.L., Kraus, V.B., Guilak, F., Olson, S.A., Olson, S.A. Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. ARTHRITIS RESEARCH&THERAPY 2014; 16(--):U305-U319. >>> Interleukin-1 receptor antagonist; Saline; SC; Mice; 2004; Controls received mp w/ vehicle; animal info (male, C57BL6, 8 weeks old); functionality of mp verified by serum levels; comparison of injection vs mp; stress/adverse reaction: (see pg. 4); post op. care (buprenorphine);"...no significant differences were detected for any of the outcome measures in mice receiving systemic saline via osmotic pump or IP injections.."pg 4; pumps removed after 28 days;.

15265 Kato, G., Shimizu, Y., Arai, Y., Suzuki, N., Sugamori, Y., Maeda, M., Takahashi, M., Tamura, Y., Wakabayashi, N., Murali, R., Ono, T., Ohya, K., Mise-Omata, S., Aoki, K., Aoki, K. The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. ARTHRITIS RESEARCH&THERAPY 2015; 17(--):U2-U15. >>> Peptide, OP3-4; PBS; DMSO; SC; Mice; Controls received mp w/ vehicle; animal info (male, DBA/1J, 7 weeks old); pumps replaced after day 35 or 42; 20% DMSO used; peptides;"a sustained-release carrier for OP3-4 needs to be developed since peptide drugs are unstable and aggregate easily in vivo. The effects of OP3-4 in this study were achieved using infusion pumps"pg 13.

13760 Dowty, M.E., Jesson, M.I., Ghosh, S., Lee, J., Meyer, D.M., Krishnaswami, S., Kishore, N. Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics 2014; 348(-1-):165-173. >>> Tofacitinib; DMSO; PEG 300; SC; Mice; Controls received mp w/ vehicle; animal info (male, DBA/1, 10-12 weeks old); functionality of mp verified by plasma levels; pumps replaced every 19 days; 33% DMSO used; dose-response (pg. 168); toxicology; immunology; Tofacitinib is a janus kinase inhibitor;.

13345 Adan, N., Guzman-Morales, J., Ledesma-Colunga, M.G., Perales-Canales, S.I., Quintanar-Stephano, A., Lopez-Barrera, F., Mendez, I., Moreno-Carranza, B., Triebel, J., Binart, N., de la Escalera, G.M., Thebault, S., Clapp, C. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. Journal of Clinical Investigation 2013; 123(-9-):3902-3913. >>> Prolactin, ovine; SC; Rat; Animal info (male, Sprague Dawley, 200-250g); functionality of mp verified by serum levels at 21 days; behavioral testing (hind paw pain); immunology;.

13196 Wei, F.Y., Moore, D.C., Li, Y.L., Zhang, G., Wei, X.C., Lee, J.K., Wei, L. Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway. ARTHRITIS RESEARCH&THERAPY 2012; 14(-4-):U233-U243. >>> AMD 3100; PBS; SC; Guinea Pig; 2006; Controls received mp w/ PBS; animal info (0.88 kg+- 0.21 kg); pumps replaced once every 6 weeks; long-term study.

12871 Schurgers, E., Mertens, F., Vanoirbeek, J.A.J., Put, S., Mitera, T., De Langhe, E., Billiau, A., Hoet, P.H.M., Nemery, B., Verbeken, E., Matthys, P. Pulmonary inflammation in mice with collagen-induced arthritis is conditioned by complete Freund's adjuvant and regulated by endogenous IFN-?. European Journal of Immunology 2012; 42(-12-):3223-3234. >>> Etanercept; PBS; Mice; 2004; Control animals received mp w/ vehicle; animal info (IFN gamma R KO, DBA/1).

12545 Clark, A.K., Grist, J., Al-Kashi, A., Perretti, M., Malcangio, M. Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model. Arthritis and Rheumatism 2012; 64(-6-):2038-2047. >>> Cathepsin S; fractalkine; CSF/CNS (intrathecal); Rat; 2001; Animal info (adult, female, Lewis, 180-200 g); peptides.

12049 Liu, D.Y., Lon, H.K., DuBois, D.C., Almon, R.R., Jusko, W.J. Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 2011; 38(-6-):769-786. >>> Anakinra; SC; Rat; Animal info (male, Lewis, 6-9 wks old); half-life"4-6 hours"pg 78; pharmacokinetic study; pk study.

11327 Evans, L., Williams, A.S., Hayes, A.J., Jones, S.A., Nowell, M. Suppression of Leukocyte Infiltration and Cartilage Degradation by Selective Inhibition of Pre B-Cell Colony-Enhancing Factor/Visfatin/Nicotinamide Phosphoribosyltransferase APO866-Mediated Therapy in Human Fibroblasts and Murine Collagen-Induced Arthritis. Arthritis and Rheumatism 2011; 63(-7-):1866-1877. >>> APO866; Propylene glycol; saline; SC; Mice; 1002; Controls received mp w/ vehicle; animal info (male, DBA/1, 7-8 wks old); half-life (~8 hours in humans pg 1876); APO866 is a small molecule inhibitor in human fibroblasts in vitro and in murine collagen arthritis; A maximum tolerated dose of APO866 of 0.126 mg/m2/hour in human clinical trials and 0.18 mg/m2/hour in rats has been reported"pg 1868.

10202 Ergang, P., Leden, P., Vagnerova, K., Klusonova, P., Miksik, I., Jurcovicova, J., Kment, M., Pacha, J. Local metabolism of glucocorticoids and its role in rat adjuvant arthritis. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2010; 323(-2-):155-160. >>> Anakinra; Saline; sodium citrate; EDTA; tween 80; SC; Rat; 2ML1; Controls received vehicle; animal info (male, Lewis, 7-9 weeks old; adjuvant-induced arthritis); IL-1B antagonist; 0.5mM EDTA; 0.1% Tween 80.

10197 Boettger, M.K., Weber, K., Gajda, M., Braeuer, R., Schaible, H.G. Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis. BRAIN BEHAVIOR AND IMMUNITY 2010; 24(-3-):474-485. >>> Ketamine, Morphine; Saline; CSF/CNS (intrathecal); Rat; 2ML4; Controls received mp w/ vehicle; tolerance; ALZET brain infusion kit used; half-life pg 477 (2.5 hrs in CSF (ketamine); 2.1 hrs (morphine)); animal info (Female, Lewis, 6-8 wks old, 160-180 g); dorsal laminectomy; behavioral testing (pain related behavior).

10149 Stolina, M., Schett, G., Dwyer, D., Vonderfecht, S., Middleton, S., Duryea, D., Pacheco, E., Van, G., Bolon, B., Feige, U., Zack, D., Kostenuik, P. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies. ARTHRITIS RESEARCH&THERAPY 2009; 11(-6-):U251-U265. >>> Anakinra; SC; Rat; Animal info (Lewis, 7 to 8 wks old, AIA, CJA).

10148 Boettger, M.K., Weber, K., Grossmann, D., Gajda, M., Bauer, R., Baer, K.J., Schulz, S., Voss, A., Geis, C., Braeuer, R., Schaible, H.G. Spinal Tumor Necrosis Factor alpha-Neutralization Reduces Peripheral Inflammation and Hyperalgesia and Suppresses Autonomic Responses in Experimental Arthritis A Role for Spinal Tumor Necrosis Factor alpha-During Induction and Maintenance of Peripheral Inflammation. Arthritis and Rheumatism 2010; 62(-5-):1308-1318. >>> Etanercept; CSF/CNS (intrathecal); Rat; 2ML4; Controls received mp w/vehicle: animal info (Lewis, 6-8 wks, 160-180 g); ALZET intrathecal catheter used; schematic drawing with ALZET pump and catheter.

9965 Dahlen, E., Barchan, K., Herrlander, D., Hoejman, P., Karlsson, M., Ljung, L., Andersson, M., Baeckman, E., Hager, A.C.M., Walse, B., Joosten, L., van den Berg, W. Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis. Journal of Immunotoxicology 2008; 5(-2-):189-199. >>> Anakinra; NaCl; citric acid; EDTA; tween 80; IP; Mice; 1007D; Anakinra is an interleukin-1 receptor antagonist; 0.35mM EDTA; 0.07% Tween 80;.

9565 Averill, S., Inglis, J.J., King, V.R., Thompson, S.W.N., Cafferty, W.B.J., Shortland, P.J., Hunt, S.P., Kidd, B.L., Priestley, J.V. Reg-2 expression in dorsal root ganglion neurons after adjuvant-induced monoarthritis. Neuroscience 2008; 155(-4-):1227-1236. >>> Nerve growth factor, recomb. human; glial-derived neurotrophic factor, recomb. human; leukemia inhibitory factor, recomb. human; Saline; albumin, rat serum; CSF/CNS (intrathecal); Rat; 2002; Controls received mp w/ vehicle; peptides, animal info (male, Wistar, 220-400 g.).

9525 Brahn, E., Banquerigo, M.L., Lee, J.K., Park, E.J., Fogler, W.E., Plum, S.M. An Angiogenesis Inhibitor, 2-Methoxyestradiol, Involutes Rat Collagen-Induced Arthritis and Suppresses Gene Expression of Synovial Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor. Journal of Rheumatology 2008; 35(-11-):2119-2128. >>> Estradiol, 2-methoxy-; SC; Rat; 2ML4; Controls received mp w/ vehicle; comparison of oral gavage vs. mp; animal info (syngeneic LOU, 8-10 wks old, 100-150 g., Collagen-induced arthritis;"Delivery of 60 mg/kg by an osmotic pump, however, was similar in efficacy to 300 mg/kg oral gavage. This result suggests that a steady-state level of 2ME2 achieved equivalent arthritic inhibition at a lower total dose."(p. 2124).

9258 Milici, A.J., Kudlacz, E.M., Audoly, L., Zwillich, S., Changelian, P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. ARTHRITIS RESEARCH&THERAPY 2008; 10(-1-):U175-U183. >>> CP-690550; PEG 300; SC; Rat; mice; 2004; 2ML2; Controls received mp w/ vehicle or no pump; dose-response (fig. 1); enzyme inhibitor (JAK3, janus kinase 3); animal info (male, DBA/J1, male, Lewis);"it was necessary to administer CP-690550 via osmotic pumps due to the poor (PK) properties of this compound in rodents.".

9197 Matsuno, H., Yoshida, K., Ochiai, A., Okamoto, M. Requirement of methotrexate in combination with anti-tumor necrosis factor alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis. Journal of Rheumatology 2007; 34(-12-):2326-2333. >>> Infliximab; immunoglobulin G, human; SC; Mice (SCID); Controls received mp w/ human IgG; immunology; animal info (SCID-HuRAg-pit, 6-7 wks old; TNF-alpha inhibitor.

9184 Knedla, A., Riepl, B., Lefevre, S., Kistella, S., Grifka, J., Straub, R.H., Gay, S., Schoelmerich, J., Mueller-Ladner, U., Neumann, E. The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis. Annals of the Rheumatic Diseases 2008; 68(-1-):124-129. >>> Interleukin-10; interleukin-1 receptor antagonist; Saline; DMSO; SC; Mice (SCID); 2004; Controls received mp w/ vehicle; functionality of mp verified by plasma levels; good methods (p.125); peptides; animal info (female, SCID, 4-5 wks old); Rheumatoid arthritis; pump and technique schematics p. 125; stability (with an excellent description of methods) was verified for 40 days @ 37C; 50% DMSO used;"... the application of proteins via osmotic pumps is an affective tool to evaluate the effects of cytokines and inhibitors in vitro."p. 128.

9160 Badlani, N., Inoue, A., Healey, R., Coutts, R., Amiel, D. The protective effect of OP-1 on articular cartilage in the development of osteoarthritis. OSTEOARTHRITIS AND CARTILAGE 2008; 16(-5-):600-606. >>> Osteogenic protein-1; Lactose; Knee (articular cavity); Rabbit; 2004; Controls received mp w/ vehicle; functionality of mp verified by separate in vivo test; peptides; post op. care ("appropriate"); animal info (New Zealand, White, 1 yr old); also known as BMP-7 or bone morphogenic protein-7; catheter was secured with polyethylene stents;"The efficacy of the (ALZET Pump) was tested in vivo before beginning the study with good results";"constant infusion of OP-1 may be the most ideal form of delivery"; long-term study; good methods.

9024 Kurosaka, D., Yoshida, K., Yasuda, J., Yasuda, C., Noda, K., Furuya, K., Ukichi, T., Kingetsu, I., Joh, K., Yamaguchi, N., Saito, S., Yamada, A. The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2007; 36(-6-):434-441. >>> Endostatin; PBS; IP; Mice; Controls received mp w/ vehicle; animal info (1J, 6 week);"compared with the once daily dosing regimen, the administration of endostatin by an osmotic pump achieved a similar arthritis-inhibiting effect at one-tenth of the dose...the administration method using osmotic pump is useful."pg. 434.

8740 Saito, H., Kojima, T., Takahashi, M., Horne, W.C., Baron, R., Amagasa, T., Ohya, K., Aoki, K. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis and Rheumatism 2007; 56(-4-):1164-1174. >>> Peptide, WP9QY; antibody, monoclonal, anti-TNF alpha; PBS; DMSO; SC; Mice; 2001; Controls received mp w/ vehicle; dose-response (fig. 1); pumps replaced every 7 days; half-life (p. 1182)"short;"peptides; animal info (male, DBA/1J, 6 weeks old, collagen induced arthritis); 10% DMSO.

8723 Geboes, L., De Klerck, B., Van Balen, M., Ketchtermans, H., Mitera, T., Boon, L., De Wolf-Peeters, C., Matthys, P. Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis. Arthritis and Rheumatism 2007; 56(-8-):2595-2607. >>> Etanercept; Water, sterile; SC; Mice; 2004; Controls received mp w/vehicle; animal info (male, DBA/1, wt, IFNgR-KO, 8-12 weeks old).

7986 Paulos, C.M., Varghese, B., Widmer, W.R., Breur, G.J., Vlashi, E., Low, P.S. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. ARTHRITIS RESEARCH&THERAPY 2006; 8(-3-):U243-U252. >>> Anakinra; SC; Rat; Animal info (female, Lewis, 200g.).

7708 De Klerck, B., Geboes, L., Hatse, S., Kelchtermans, H., Meyvis, Y., Vermeire, K., Bridger, G., Billiau, A., Schols, D., Matthys, P. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. ARTHRITIS RESEARCH&THERAPY 2005; 7(-6-):R1208-R1220. >>> AMD 3100; SC; Mice; 2002; Controls received mp w/ PBS; immunology; animal info (male, 8-12 weeks).

7656 Gaitan, G., Ahuir, F.J., Herrero, J.F. Enhancement of fentanyl antinociception by subeffective doses of nitroparacetamol (NCX-701) in acute nociception and in carrageenan-induced monoarthritis. LIFE SCIENCES 2005; 77(-1-):85-95. >>> Fentanyl; Saline; SC; Rat; 2ML1; Controls received mp w/ vehicle; tolerance; animal info (male, Wistar, 250-320 g).

6975 Tamamura, H., Fujisawa, M., Hiramatsu, K., Mizumoto, M., Nakashima, H., Yamamoto, N., Otaka, A., Fujii, N. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Letters 2004; 569(-1-3-):99-104. >>> TN14003, 4F-benzoyl-; PBS; SC; Mice; 1007D; 2002; Controls received mp w/ vehicle; dose-response (Fig.2); immunology; peptides.

6926 Zwerina, J., Hayer, S., Tohidast-Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., Schett, G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis - Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis and Rheumatism 2004; 50(-1-):277-290. >>> Interleukin-1, receptor antagonist; SC; Mice (transgenic); 2004; .

6128 Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J.A., Hooper, A., Priller, J., De Klerck, B., Compernolle, V., Daci, E., Bohlen, P., Dewerchin, M., Herbert, J.M., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak, H.F., Hicklin, D.J., Carmeliet, P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine 2002; 8(-8-):831-840. >>> Placental growth factor; vascular endothelial growth factor; SC; Mice; 2001; Angiogenesis.

5590 Coxon, A., Bolon, B., Estrada, J., Kaufman, S., Scully, S., Rattan, A., Duryea, D., Hu, Y.L., Rex, K., Pacheco, E., Van, G., Zack, D., Feige, U. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis and Rheumatism 2002; 46(-10-):2604-2612. >>> Interleukin-1 receptor antagonist; Saline; sodium citrate; EDTA; Tween 80; SC; Rat; 2ML1; Controls received mp w/ BSA"to control for nonspecific anti-angiogenic effects of stress associated with implantation of the osmotic minipump."(p. 2605); implantation of pumps delivering BSA caused no angiogenesis; 0.5mM EDTA; 0.1% Tween 80;.

5220 Matsuno, H., Yudoh, K., Katayama, R., Nakazawa, F., Uzuki, M., Sawai, T., Yonezawa, T., Saeki, Y., Panayi, G.S., Pitzalis, C., Kimura, T. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology 2002; 41(--):329-337. >>> Tumor necrosis factor-a; Interleukin-6; Serum, fetal bovine; Culture medium, RPMI 1640; SC; Mice (SCID); 1007D; controls received mp w/ vehicle; functionality of mp verified by serum cytokine levels; immunology; peptides; cytokines were recombinant; pump incorrectly called an osmium pump (p. 331); agents administered singly..

5170 Scharstuhl, A., Glansbeek, H.L., van Beuningen, H.M., Vitters, E.L., van der Kraan, P.M., Van Den Berg, W.B. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. Journal of Immunology 2002; 169(--):507-514. >>> Transforming Growth Factor-B2, soluble receptor; Polymyxin B; IP; mice; 1007D; 2002; Arthritis; controls received empty pumps or mp w/ vehicle; functionality of mp verified by residual aspiration; pumps replaced after 14 days; stability verified by ELISA after infusion (p. 508, 510); soluble TGF-B RII selectively inhibits transforming growth factor-B; peptides; polymyxin B included as endotoxin inhibitor; 2002 pumps used for 7 and 14 day administration, 21-day group received a 1007D pump for final 7 days.

 

Since 1977, scientist around the world have used ALZET pumps to conduct their research, publishing their results in high-impact journals. The ALZET bibliography now contains over 16,000 publications! We can perform a custom search for references relevant to your research.

Request your ALZET bibliography search!

 

Order the ALZET SurgicalImplantation Video

What researchers are saying...

“Angiostatin was administered through continuous infusion...the continuous administration of angiogenesis inhibitors has greater therapeutic efficacy than the more commonly used twice-daily injections.” (p. 80) Reijneveld et al., European Journal of Clinical Investigation 2003;33:76-81.